Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Sieber, Julia ^a,b   Daridon, Capucine ^a,b   Fleischer, Sarah J ^a,b   Fleischer, Vanessa ^a,b   Hiepe, Falk ^a,b   Alexander, Tobias ^a,b   Heine, Guido ^a   Burmester, Gerd R ^a   Fillatreau, Simon ^b   Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TOLL LIKE RECEPTOR 9; VASCULOTROPIN; TLR9 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

ADULT; B-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 84924334062     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0477-1     Document Type: Article

References (41)

1. Tsokos GC: Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
2. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
3. Wahren-Herlenius M, Dorner T: Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013, 382:819-831.
4. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I: Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
5. Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, Hiesberger H, Smolen JS, Graninger WB: Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 2001, 40:876-881.
6. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, Radda I, Smole JS, Graninger WB: Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002, 11:102-108.
7. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L: Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2524-2532.
8. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005, 1050:34-39.
9. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W: Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
10. Ronnblom L, Pascual V: The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008, 17:394-399.
11. Obermoser G, Pascual V: The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010, 19:1012-1019.
12. Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA: Pro-inflammatory adaptive cytokines and shed tumor necrosis factor receptors are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 2014, 66:1888-1899.
13. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM: B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
14. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, Fillatreau S, Gray D: B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012, 209:1001-1010.
15. Lund FE: Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008, 20:332-338.
16. Anolik JH: B cell biology: implications for treatment of systemic lupus erythematosus. Lupus 2013, 22:342-349.
17. Agrawal S, Gupta S: TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 2011, 31:89-98.
18. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996, 93:2879-2883.
19. Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Wullner M, Tluk S, Hartmann H, Kritzler A, Muller C, Schetter C, Krieg AM: CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 2004, 10:431-438.
20. Celhar T, Magalhaes R, Fairhurst AM: TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012, 53:58-77.
21. Zorro S, Arias M, Riano F, Paris S, Ramirez LA, Uribe O, Garcia LF, Vasquez G: Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009, 18:718-726.
22. Zeuner RA, Klinman DM, Illei G, Yarboro C, Ishii KJ, Gursel M, Verthelyi D: Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides. Rheumatology 2003, 42:563-569.
23. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
24. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP, OC-SELENA Trial: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005, 353:2550-2558.
25. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dorner T: Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009, 113:2461-2469.
26. Heine G, Niesner U, Chang HD, Steinmeyer A, Zugel U, Zuberbier T, Radbruch A, Worm M: 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur J Immunol 2008, 38:2210-2218.
27. Heine G, Drozdenko G, Grun JR, Chang HD, Radbruch A, Worm M: Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. Eur J Immunol 2014, 44:1615-1621.
28. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF: Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
29. Chen M, Zhang W, Xu W, Zhang F, Xiong S: Blockade of TLR9 signaling in B cells impaired anti-dsDNA antibody production in mice induced by activated syngenic lymphocyte-derived DNA immunization. Mol Immunol 2011, 48:1532-1539.
30. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW: Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010, 159:11-22.
31. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006, 54:3601-3611.
32. Mu R, Sun XY, Lim LT, Xu CH, Dai CX, Su Y, Jia RL, Li ZG: Toll-like receptor 9 is correlated to disease activity in Chinese systemic lupus erythematosus population. Chin Med J (Engl) 2012, 125:2873-2877.
33. Chauhan SK, Singh VV, Rai R, Rai M, Rai G: Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation. J Clin Immunol 2013, 33:954-964.
34. Liew FY, Xu D, Brint EK, O'Neill LA: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5:446-458.
35. Nickerson KM, Christensen SR, Cullen JL, Meng W, Luning Prak ET, Shlomchik MJ: TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013, 190:1447-1456.
36. Arend WP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991, 88:1445-1451.
37. Mauri C, Gray D, Mushtaq N, Londei M: Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003, 197:489-501.
38. Arend WP: The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002, 13:323-340.
39. Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886.
40. Angeli V, Ginhoux F, Llodra J, Quemeneur L, Frenette PS, Skobe M, Jessberger R, Merad M, Randolph GJ: B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 2006, 24:203-215.
41. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R: Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011, 186:4794-4804.